Figure 2From: MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancerMYC promotes survival in antiestrogen resistant cells. A, Western blot, reduced MYC in LCC9 cells at 48 h with MYC siRNA compared to control siRNA. Actin is a loading control. B, Quantitation of MYC in in LCC9 cell show 60% reduction in MYC siRNA transfected cells compared with control siRNA. C, MYC siRNA interacted additively (RI = 1.11) with ICI in inhibiting cell number in LCC1 but not in LCC9 cells. Bars,mean ± SE of relative cell number (normalized to vehicle controls) for a representative experiment performed in sextuplicate. ANOVA, p < 0.001; *p < 0.05 for treatment versus control for respective cell lines. ^, p < 0.05 for LCC1 versus LCC9 cells with MYC siRNA + ICI. D, LCC9 cells showed increased sensitivity to 10058-F4compared with LCC1 cells at 48 h. Points, mean of cell number; bars, ±SE. E, 10058-F4 or ICI alone or the combination for 48 h inhibit cell number in LCC1. In LCC9 cells, RI = 1.51, suggest a modest synergistic interaction between ICI and 10058-F4; ANOVA, p < 0.001; *p < 0.05 for treatment versus control for respective cell lines. ^, p < 0.05 for ICI + 10058-F4 versus 10058-F4. F, Western blot show decrease in MYC, MAX, BCL2 and an increase in cleaved CASP7 , with 10058-F4 (MI: MYC inhibitor) or ICI + 10058-F4 (C: combination) compared with vehicle (V) alone or with ICI alone (I) treatment (48 h). G, Annexin V-FITC (apoptosis) in LCC1 and LCC9 cells with vehicle, ICI , 10058-F4 , or ICI + 10058-F4 (combination). ANOVA, p < 0.001; *p < 0.05 for indicated treatment versus vehicle control for respective cells lines. Paclitaxel, a positive control for apoptosis. H, Dot plots showcells positive for annexin-V-FITC (x-axis) and propidium iodide (PI; y-axis).Back to article page